Market Research Logo

Taiwan Pharmaceuticals and Healthcare Report Q2 2016

Taiwan Pharmaceuticals and Healthcare Report Q2 2016

BMI View: Pricing and reimbursement will remain a challenge for pharmaceutical firms operating in Taiwan. The turnaround of the National Health Insurance's budget from a deficit to a surplus will further perpetuate such measures as it had been key to curbing pharmaceutical spending in the country. Central measures such as the drug expenditure target and reference pricing are particularly tough while pricevolume agreements present financial risks to firms. .

Headline Expenditure Projections

Pharmaceuticals: TWD167.7bn (USD5.5bn) in 2014 to TWD175.1bn (USD5.5bn) in 2015; +4.4% in local currency terms and -0.1% in US dollar terms.

Healthcare: TWD1,005.4bn (USD33.2bn) in 2014 to TWD1,046.8bn (USD33.0bn) in 2015; +4.1% in local currency terms and -0.4%% in US dollar terms.


BMI Industry View
Table: Headline Pharmaceuticals & Healthcare Forecasts (Taiwan 2014-2020)
SWOT
Industry Forecast
Pharmaceutical Market Forecast
Table: Pharmaceutical Sales, Historical Data And Forecasts (Taiwan 2012-2020)
Healthcare Market Forecast
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Taiwan 2012-2020)
Prescription Drug Market Forecast
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Taiwan 2012-2020)
Patented Drug Market Forecast
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Taiwan 2012-2020)
Generic Drug Market Forecast
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Taiwan 2012-2020)
OTC Medicine Market Forecast
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Taiwan 2012-2020)
Pharmaceutical Trade Forecast
Table: Pharmaceutical Trade Data And Forecasts (Taiwan 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Taiwan 2014-2020)
Industry Risk/Reward Index
Asia Pacific Risk/Reward Index
Taiwan Risk/Reward Index
Rewards
Risks
Regulatory Review
Table: Medicine Categories In Taiwan
Table: Examples Of Controlled Drugs In Taiwan
Intellectual Property Issues
Pricing Regime
Reimbursement Regime
Table: Reimbursement System in Taiwan
Table: Drug Reimbursement Principles
Table: BNHI Spending By Type Of Outpatient Claims, As Percentage Of Total
Market Overview
Market Overview
Healthcare Sector
Table: Sources Of Financing
Table: Healthcare Resources (Taiwan 2010-2015)
Table: Healthcare Personnel (Taiwan 2010-2015)
Table: Healthcare Activity (Taiwan 2010-2015)
Research & Development
Clinical Trials
Epidemiology
Competitive Landscape
Research-Based Industry
Table: Corporate Member Companies Of IRPMA
Table: Multinational Market Activity
Generic Drugmakers
Table: Top-20 Pharmaceutical & Biotechnology Firms In Taiwan According To Market Capitalisation (USDmn)
Table: TGPA Members, 2012
Pharmaceutical Distribution
Pharmaceutical Retail Sector
Company Profile
GlaxoSmithKline (GSK)
Merck & Co
Novartis
Pfizer
ScinoPharm Taiwan
TaiGen
Yung Shin Pharmaceutical (YSP)
Demographic Forecast
Table: Population Headline Indicators (Taiwan 1990-2025)
Table: Key Population Ratios (Taiwan 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Taiwan 1990-2025)
Table: Population By Age Group (Taiwan 1990-2025)
Table: Population By Age Group % (Taiwan 1990-2025)
Glossary
Methodology
Pharmaceutical Expenditure Forecast Model
Healthcare Expenditure Forecast Model
Notes On Methodology
Risk/Reward Index Methodology
Index Overview
Table: Pharmaceutical Risk/Reward Index Indicators
Indicator Weightings

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report